Constructs and libraries comprising antibody surrogate light chain sequences

Abstract

The invention concerns constructs and libraries comprising antibody surrogate light chain sequences. In particular, the invention concerns constructs comprising VpreB sequences, optionally partnered with another polypeptide, such as, for example, antibody heavy chain variable domain sequences, and libraries containing the same.

1 - 88 . (canceled) 
     
     
         89 . A polypeptide comprising a fusion of a VpreB1 sequence of SEQ ID NO: 1, or a fragment thereof, or a variant thereof having at least about 70% sequence identity to SEQ ID NO: 1, directly fused to a λ5 sequence of SEQ ID NO: 6, or a fragment thereof, or a variant thereof having at least about 85% sequence identity to SEQ ID NO: 6, conjugated to an antibody heavy chain sequence comprising a variable region, wherein said conjugate specifically binds to a target. 
     
     
         90 . The polypeptide of  claim 89  wherein said VpreB1 sequence is fused at its C-terminus to the N-terminus of said λ5 sequence. 
     
     
         91 . The polypeptide of  claim 89  wherein the fusion takes place at or around the CDR3 analogous regions of said VpreB1 sequence and λ5 sequence, respectively. 
     
     
         92 . The polypeptide of  claim 89  wherein the VpreB1 fragment comprises amino acid residues 20 to 115 of SEQ ID NO: 1. 
     
     
         93 . The polypeptide of  claim 89  or  claim 92  wherein the λ5 fragment comprises amino acid residues 87 to 105 of SEQ ID NO: 6. 
     
     
         94 . The polypeptide of  claim 89  comprising the fusion of SEQ ID NO: 10 or SEQ ID NO: 12. 
     
     
         95 . The polypeptide of  claim 89  comprising the VpreB1 sequence of SEQ ID NO: 1 and the λ5 sequence of SEQ ID NO: 6, wherein the direct fusion take place between an amino acid residue from position 116 to position 126 of SEQ ID NO: 1 and an amino acid residue from position 82 to 93 of SEQ ID NO: 6. 
     
     
         96 . The polypeptide of  claim 95  wherein the direct fusion take place at amino acid residue 121 of SEQ ID NO: 1. 
     
     
         97 . The polypeptide of  claim 89  wherein said fusion is conjugated to said antibody heavy chain sequence by a peptide linker or by non-covalent association to dorm a dimeric complex. 
     
     
         98 . The polypeptide of  claim 89  wherein said target is an antigen. 
     
     
         99 . The polypeptide of  claim 98  wherein the antigen is a viral antigen. 
     
     
         100 . The polypeptide of  claim 99  wherein the viral antigen is an influenza virus. 
     
     
         101 . The polypeptide of  claim 100 , wherein said polypeptide neutralizes said influenza virus.